KPV
Also known as: Lys-Pro-Val, alpha-MSH C-terminal tripeptide
Quick summary
KPV is the final three amino acids of alpha-melanocyte-stimulating hormone. Research focus: NF-kappaB signaling, PepT1 transport and intestinal inflammation models. This page leads with SRP's low-and-slow starting dose.
3D structure
Overview
KPV is the final three amino acids of alpha-melanocyte-stimulating hormone. It enters cells through the PepT1 transporter. Research looks at how it dampens NF-kappaB inflammatory signaling in gut epithelial and immune cells.
Looking for research material? Simple Research Peptides lists KPV Research Peptide Vials | 30 mg, 20 mg & 10 mg for laboratory research use.
Mechanism
The last three amino acids of alpha-MSH. It reduces NF-κB inflammatory signaling in gut and skin models.
Research areas
- NF-kappaB signaling
- PepT1 transport
- intestinal inflammation models
Storage & reconstitution
Supplied as a lyophilized powder; keep sealed, dry and away from light, ideally frozen or refrigerated for long-term holding. Laboratories typically reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, then hold the solution refrigerated (2–8 °C) and use it within the window set by their own stability protocol.
Recommended starting dose (low and slow)
| Starting dose | Low end of the studied range: 200 mcg; 250 mcg; 200 mcg. |
|---|---|
| Frequency | Reported schedules: daily; 250mcg-1mg daily; Daily. |
| Reconstitution | Examples: 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL; 10mg vial + 2mL diluent (as listed). storage note: Reconstituted: refrigerate, used within 4 weeks. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Top of the studied range: 500 mcg; 1 mg; 500 mcg. These are range tops, not verified ceilings. Reported amounts vary by 2x or more. |
|---|
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks, with a white-cell differential.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is KPV studied for?
In research it is studied for NF-kappaB signaling, PepT1 transport and intestinal inflammation models. The last three amino acids of alpha-MSH.
How is KPV given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026